Public Market Listing
Live quotes, historical charts, and market capitalization for Keymed Biosciences are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(6 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | BCMA x CD3Multispecific antibody | Multiple Myeloma | |
| Phase 3 | CD38Monoclonal antibody | Multiple Myeloma | |
| Phase 3 | TSLPMonoclonal antibody | Chronic Obstructive Pulmonary DiseaseAsthma | |
| Phase 3 | IL-4R-alphaMonoclonal antibody | Atopic DermatitisChronic Obstructive Pulmonary DiseaseAsthmaPrurigo Nodularis | |
| Phase 2 | TSLP + IL-13Multispecific antibody | Atopic DermatitisChronic Obstructive Pulmonary DiseaseAsthmaChronic Spontaneous Urticaria | |
| Phase 1 | Amyloid-beta (monoclonal antibody)Monoclonal antibody | Alzheimer's Disease |
Upcoming events
(16 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
2027 (9)
February 2027 (1)
What to watch
March 2027 (1)
What to watch
July 2027 (1)
September 2027 (1)
What to watch
November 2027 (3)
What to watch
What to watch
What to watch
December 2027 (2)
What to watch
2028 (3)
March 2028 (1)
May 2028 (1)
2030 (1)
May 2030 (1)
What to watch
Regulatory and conference events
(4)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (3)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-H1 | $69M | — | — | $11M | report ↗ |
Keymed Biosciences reported revenue of $68.99M, up 809.0% YoY and a quarterly net burn of $10.88M for H1 2025.
Figures only: this period's report disclosed no narrative text
View 2 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-H1 | $7.6M | $46M | $355M | $47M | report ↗ |
| 2023-H1 | — | $36M | — | — | report ↗ |
Annual history (4 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $100M | $100M | $280M | $73M | report ↗ |